Steroids, Hyaluronic Acid or Platelet Rich Plasma Versus Placebo for the Knee Osteoarthritis
Launched by BALGRIST UNIVERSITY HOSPITAL · May 17, 2016
Trial Information
Current as of June 30, 2025
Completed
Keywords
ClinConnect Summary
Osteoarthritis of the knee joint is a very common disease in middle aged and elderly patients. This study evaluates the efficiency of different commonly used substances for intraarticular, non-operative treatment in early stages of this disease.
120 patients receive an fluoroscopic guided injection in the knee joint: 30 patients get injection with steroids 30 patients get injection with prp 30 patients get injection with hyaluronic acid 30 patients get injection with placebo (iopamiro contrast media)
Primary outcome: - clinical outcome (pain using numeric rating scale)
* Magnetic Resonan...
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • gonarthritis Kellgren 1,2,3 with symptoms
- • german speaking
- • informed consent
- Exclusion criteria:
- • -age under 18, gonarthritis, Kellgren 4, anticoagulation therapy, known inflammatory disease or infection, cardiovascular disease NYHA IV, immunosuppression, contraindication for MRI, pregnancy, no informed consent, NSAR 3 days before injection, etc.
About Balgrist University Hospital
Balgrist University Hospital is a leading academic medical center based in Zurich, Switzerland, renowned for its expertise in musculoskeletal health and rehabilitation. As a prominent sponsor of clinical trials, the hospital is dedicated to advancing medical research and improving patient outcomes through innovative studies in orthopedics, neurology, and rehabilitation sciences. With a strong commitment to interdisciplinary collaboration and patient-centered care, Balgrist University Hospital leverages its state-of-the-art facilities and a team of experienced researchers to drive clinical advancements and foster the translation of scientific discoveries into practical therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zurich, , Switzerland
Patients applied
Trial Officials
Andrea B Rosskopf, MD
Principal Investigator
Radiology University Hospital Balgrist
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials